IMBRUVICA® has demonstrated long-term outcomes across all patient subgroups
IMBRUVICA® is the only novel targeted therapy proven to keep 8 out of 10 patients alive at up to 7 years*
With overall survival benefits supported by experience in clinical trials and the real world.
Only IMBRUVICA® keeps 6 out of 10 patients alive and progression-free at up to 7 years†
A groundbreaking benchmark in CLL treatment.
IMBRUVICA® is a preferred firstline treatment in patients with uIGHV CLL.
IMBRUVICA® is the only novel targeted therapy with proven long-term survival benefits in high-risk patients with Genetic aberrations.‡
IMBRUVICA® has demonstrated long-term survival outcomes.
IMBRUVICA® offers the reassurance of the longest follow-up of any novel targeted therapy in R/R CLL
Component not published? componentType is undefined.
Only IMBRUVICA® offers long-term survival outcomes in patients with R/R CLL, up to 8 years.
IMBRUVICA® is now a preferred treatment across all CLL patient subtypes, as recommended by ESMO guidelines
ESMO guidelines recommend IMBRUVICA®-based therapy for patients with CLL
Adapted from Eichhorst B, et al. 2021.
Read more about IMBRUVICA® for the treatment of CLL in the ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of chronic lymphocytic leukaemia.
Learn about IMBRUVICA® in CLL
Explore the predictable long-term
safety profile of IMBRUVICA®
*At 6.5 years, overall survival was estimated to be 78% in IMBRUVICA® patients.
†At 6.5 years, 61% vs 9% of IMBRUVICA® vs. Clb patients were estimated to be progression-free and alive.
‡Up to 95.9 months of follow-up.
Clb=chlorambucil; CLL=chronic lymphocytic leukaemia; R/R=relapsed/refractory; uIGHV=unmutated immunoglobulin heavy-chain variable region.
